Letters to the Editor by McKenna, Michael J.
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Dear Sir:
Dr. Dedrick's perceptive comments regarding our
paper on vinylidene chloride (I) are much ap-
preciated. The discrepancy between the text and
Figure 2 was an oversight in preparation of the
manuscript. For clarification, Figure 1 shows
the relationship between the total metabolism
of VDC and depletion of hepatic glutathione in
rats following a single 6 hr inhalation exposure.
The nonlinear character of VDC metabolism is
more appropriately shown in this figure. Since the
majority of VDC metabolites are represented by
glutathione conjugates the apparent dependence of
VDC metabolism on the availability of GSH is not
surprising. When viewed in the context of the co-
valent binding data shown in Figure lb ofDr. Ded-
rick's letter, it is apparent that detoxification of
VDC is saturable, whereas the production of a
reactive intermediate capable of alkylating tissue
macromolecules is a linear function of VDC expo-
sure concentrations over the range examined. The
data clearly indicate a saturation of detoxification
pathways for VDC prior to an effect on pathways
leading to alkylation ofhepatic macromolecules.
Dr. Dedrick's thoughts on pharmacokinetics and
risk assessment are certainly consistent with the
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efforts of this laboratory over the recent past. The
specific problem of vinyl chloride risk assessment
and the role of pharmacokinetic considerations
therein has been dealt with in detail in two recent
publications from this laboratory (2, 3). Therefore I
will make only one additional comment regarding
the problems of extrapolation of dose-response re-
lationships such as those shown in Figure 3 of Dr.
Dedrick's letter.
Just as extrapolation from a single high dose
tends to underestimate the effect ofinterest at lower
doses, it can also be seen that extrapolation from
two high doses on the upper portion of the curve
would provide agross overestimate ofthe effects at
lower doses. The point to be made is simply that
neither procedure provides an adequate risk as-
sessment. Such considerations are important not
only to the interpretation of hazard evaluation
studies but also their design. In both instances the
primary objective should be a well-defined dose-
response relationship, which includes consid-
erations of metabolic activation, thereby providing
a sounddatabase forrisk assessment.
MICHAEL J. MCKENNA
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